Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.

Vijay A. Doraiswamy, Marvin J Slepian, Martin G. Gesheff, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The pharmacologic management of patients with high-risk coronary artery disease consists of aspirin and a P2Y12 receptor inhibitor. Chronic oral anticoagulation with warfarin is the major treatment strategy to attenuate thromboembolism or stroke in patients with deep vein thrombosis, pulmonary embolism, heart failure and atrial fibrillation. A substantial percentage of the latter group of patients have coronary artery disease and may require stenting with long-term dual antiplatelet therapy in addition to therapy with warfarin to reduce arterial ischemic events in addition to stroke. These new oral anticoagulants have been developed for long-term therapy to overcome the limitations of warfarin. Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored.

Original languageEnglish (US)
Pages (from-to)1259-1267
Number of pages9
JournalExpert Review of Cardiovascular Therapy
Volume11
Issue number9
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Anticoagulants
Coronary Artery Disease
Warfarin
Stroke
Antithrombins
Thromboembolism
Therapeutics
Acute Coronary Syndrome
Pulmonary Embolism
Venous Thrombosis
Atrial Fibrillation
Aspirin
Heart Failure
Dabigatran

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Potential role of oral anticoagulants in the treatment of patients with coronary artery disease : focus on dabigatran. / Doraiswamy, Vijay A.; Slepian, Marvin J; Gesheff, Martin G.; Tantry, Udaya S.; Gurbel, Paul A.

In: Expert Review of Cardiovascular Therapy, Vol. 11, No. 9, 09.2013, p. 1259-1267.

Research output: Contribution to journalArticle

Doraiswamy, Vijay A. ; Slepian, Marvin J ; Gesheff, Martin G. ; Tantry, Udaya S. ; Gurbel, Paul A. / Potential role of oral anticoagulants in the treatment of patients with coronary artery disease : focus on dabigatran. In: Expert Review of Cardiovascular Therapy. 2013 ; Vol. 11, No. 9. pp. 1259-1267.
@article{3e514588f86243408a1c1e6a046aede7,
title = "Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.",
abstract = "The pharmacologic management of patients with high-risk coronary artery disease consists of aspirin and a P2Y12 receptor inhibitor. Chronic oral anticoagulation with warfarin is the major treatment strategy to attenuate thromboembolism or stroke in patients with deep vein thrombosis, pulmonary embolism, heart failure and atrial fibrillation. A substantial percentage of the latter group of patients have coronary artery disease and may require stenting with long-term dual antiplatelet therapy in addition to therapy with warfarin to reduce arterial ischemic events in addition to stroke. These new oral anticoagulants have been developed for long-term therapy to overcome the limitations of warfarin. Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored.",
author = "Doraiswamy, {Vijay A.} and Slepian, {Marvin J} and Gesheff, {Martin G.} and Tantry, {Udaya S.} and Gurbel, {Paul A.}",
year = "2013",
month = "9",
language = "English (US)",
volume = "11",
pages = "1259--1267",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Potential role of oral anticoagulants in the treatment of patients with coronary artery disease

T2 - focus on dabigatran.

AU - Doraiswamy, Vijay A.

AU - Slepian, Marvin J

AU - Gesheff, Martin G.

AU - Tantry, Udaya S.

AU - Gurbel, Paul A.

PY - 2013/9

Y1 - 2013/9

N2 - The pharmacologic management of patients with high-risk coronary artery disease consists of aspirin and a P2Y12 receptor inhibitor. Chronic oral anticoagulation with warfarin is the major treatment strategy to attenuate thromboembolism or stroke in patients with deep vein thrombosis, pulmonary embolism, heart failure and atrial fibrillation. A substantial percentage of the latter group of patients have coronary artery disease and may require stenting with long-term dual antiplatelet therapy in addition to therapy with warfarin to reduce arterial ischemic events in addition to stroke. These new oral anticoagulants have been developed for long-term therapy to overcome the limitations of warfarin. Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored.

AB - The pharmacologic management of patients with high-risk coronary artery disease consists of aspirin and a P2Y12 receptor inhibitor. Chronic oral anticoagulation with warfarin is the major treatment strategy to attenuate thromboembolism or stroke in patients with deep vein thrombosis, pulmonary embolism, heart failure and atrial fibrillation. A substantial percentage of the latter group of patients have coronary artery disease and may require stenting with long-term dual antiplatelet therapy in addition to therapy with warfarin to reduce arterial ischemic events in addition to stroke. These new oral anticoagulants have been developed for long-term therapy to overcome the limitations of warfarin. Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored.

UR - http://www.scopus.com/inward/record.url?scp=84901112445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901112445&partnerID=8YFLogxK

M3 - Article

C2 - 23968500

AN - SCOPUS:84901112445

VL - 11

SP - 1259

EP - 1267

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 9

ER -